Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietMedicationAging & DiabetesIssue 671

Metformin May Slow Aging Process

Worms treated with metformin live longer. The drug may slow the aging process by mimicking the effects of dieting....
Advertisement

A recent study grew Caenorhabditis elegans worms in the presence of E.Coli bacteria and observed the effects of metformin on the aging process. The results showed the worms that were treated with metformin had lived longer when the E.Coli strain was sensitive to the medication. In fact, the metformin increased their lifespan by 6 days, which is one-third of their usual life expectancy.

The way that metformin slows the aging process is by changing the metabolism process in the bacteria. By doing so, the bacteria restrict the nutrients that are available to the worm. This process has a similar effect to diet restriction in the body.

To isolate the metabolic pathways affected by metformin, the researchers included strains of E.Coli that had defective genes linked to metabolism and controlled the levels of nutrients available to the bacteria. The results revealed that metformin disturbed the bacteria's metabolism of folate and methionine. These are both building blocks to protein and any disruption can limit the nutrients that are available to the worm. This decrease in nutrients available to the host mimics diet restriction and allows the worm to live longer. However, when the worm was given excess sugar in its diet, the metformin did not delay the aging process.

In the gut, bacteria play an important role in nutrient digestion from food. Metabolic diseases including obesity, diabetes, inflammatory bowel disease, and cancer have been associated with defective gut bacteria. Even though metformin's anti-aging mechanism has not been proven in humans, this study may lead to future ways of preventing metabolic diseases.

Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism. Cell, 2013; 153 (1): 228 DOI: 10.1016/j.cell.2013.02.035 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  DietMedicationAging & DiabetesIssue 671

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75